NATIONAL REGIONAL MEDICAL CENTER FOR ONCOLOGY · TOP-RANKED CANCER SPECIALTY HOSPITAL
Fudan University Shanghai Cancer Center (FUSCC)
Founded in 1931 as the Sino-Belgian Radium Institute, Fudan University Shanghai Cancer Center (FUSCC) is China’s oldest and most renowned specialized tertiary oncology hospital. Ranked #1 among specialized cancer hospitals in East China and consistently top-2 nationwide, FUSCC is the central driver of national cancer guidelines and global oncology clinical trials.
FUSCC handles over 50,000 cancer surgical procedures and 1.8 million oncology visits annually. Globally celebrated for creating the ‘Fudan Molecular Classification’ for triple-negative breast cancer, pioneering minimally invasive thoracic sublobar resections, and comprehensive colorectal liver metastasis MDTs.
FOUR CLINICAL EXCELLENCE PILLARS
Core Surgical & Oncologic Capabilities
FUSCC combines unmatched surgical volume with international leadership in molecular pathology and innovative clinical trials.
Breast Cancer Center
Pioneers of the ‘Fudan Classification’ for triple-negative breast cancer and precision oncoplastic breast reconstruction.
Thoracic VATS Surgery
World leader in sublobar ground-glass nodule (GGN) resection and radical minimally invasive esophageal surgery.
Gastrointestinal MDT
Integrated multidisciplinary protocols for complex colorectal liver metastases, HIPEC, and sphincter preservation.
Precision Radiotherapy
TrueBeam STx, EDGE radiosurgery, and direct linkage with the adjacent Shanghai Proton and Heavy Ion Center.
INTERNATIONALLY CELEBRATED ONCOLOGY CHAIRS
Academic Faculty & Department Leadership
Steered by world authorities whose clinical guidelines are adopted across international oncology congresses.
Prof. Shao Zhimin, MD, PhD
Creator of the ‘Fudan Molecular Classification’ for triple-negative breast cancer, which revolutionized precision treatment for TNBC globally. Prof. Shao leads China’s highest-volume breast surgical oncology service.
Prof. Chen Haiquan, MD, PhD
International authority on sublobar resection for early-stage lung cancer and pre-invasive ground-glass opacities, advocating for organ preservation and exceptional post-operative quality of life.
CASE INTAKE & SPECIALIST TRIAGE
Initiate Your Case Review with Fudan Cancer Center
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential FUSCC comprehensive oncology pathways in China and assist you in gathering the specific medical records needed for expert hospital review.
PATIENT INQUIRIES
Frequently Asked Questions About Fudan Cancer Center
Key clinical, logistical, and technical facts regarding international admissions, surgical evaluations, advanced technology access, and personalized care coordination at Fudan Cancer Center.
FUSCC pioneered the ‘Fudan Molecular Classification’, subtyping TNBC into four distinct categories: luminal androgen receptor (LAR), immunogenic (IM), basal-like immune-suppressed (BLIS), and mesenchymal (MES). Each subtype receives targeted therapy (e.g., anti-androgens, immunotherapy, PARP inhibitors) rather than generic chemotherapy.
Yes. FUSCC operates China’s largest Phase I Clinical Trial Center, conducting over 400 active clinical trials. International patients who meet inclusion criteria can gain access to breakthrough novel ADCs, bispecific antibodies, and cellular therapies.
Through our expedited green channel, international patients with complete pre-operative workups can typically undergo surgical resection within 3 to 7 business days of admission.
Yes. We coordinate certified remote multidisciplinary tumor board (MDT) consultations with FUSCC department chiefs, delivering a comprehensive written second-opinion report within 48 to 72 hours.
MODERN CLINICAL INFRASTRUCTURE
Strategic Multi-Campus Setup & International Transit
Modern clinical hubs designed for seamless aeromedical transport, multidisciplinary conferences, and dedicated international inpatient care.
Xuhui Historic Campus
270 Dong’an Road, Xuhui District, Shanghai
Primary surgical and inpatient headquarters in downtown Shanghai, housing specialized tumor board rooms and pathology labs.
Pudong Modern Campus
399 Kangxin Road, Pudong New Area, Shanghai
Advanced translational cancer center integrated with Phase I clinical trial facilities and particle radiotherapy synergy.